NYMC Faculty Publications
Ibrutinib Plus CIT for R/R Mature B-NHL in Children (SPARKLE Trial): Initial Safety, Pharmacokinetics, and Efficacy
DOI
10.1038/s41375-020-0749-5
Journal Title
Leukemia
First Page
2271
Last Page
2275
Document Type
Article
Publication Date
8-2020
Department
Pediatrics
Second Department
Health Behavior and Community Health
Keywords
Adolescent, Child, Child, Preschool, Combined Modality Therapy, Female, Humans, Immunotherapy, Lymphoma, B-Cell, Male, Pyrazoles, Pyrimidines
Disciplines
Medicine and Health Sciences
Recommended Citation
Burke, G. A., Beishuizen, A., Bhojwani, D., Burkhardt, B., Minard-Colin, V., Norris, R. E., Kabickova, E., Pinarli, F. G., Tacyildiz, N., Howes, A., de Jong, J., Liu, G., Nottage, K., Salman, M., de Trixhe, X. W., & Cairo, M. (2020). Ibrutinib Plus CIT for R/R Mature B-NHL in Children (SPARKLE Trial): Initial Safety, Pharmacokinetics, and Efficacy. Leukemia, 34 (8), 2271-2275. https://doi.org/10.1038/s41375-020-0749-5
COinS
